To evaluate if enalapril treatment can influence skeletal muscle metabolism and histology we investigated 26 patients with congestive heart failure and 20 normal subjects. The patients were treated with enalapril for 3 months in addition to diuretics and digitalis. Biopsies from the lateral vastus muscle were taken before and after treatment. Citrate synthetase, 3-hydroxyacyl-CoA dehydrogenase and phosphorylase activities were significantly decreased in the patients compared with controls. The number of capillaries per fibre and the number of capillaries surrounding each fibre were significantly decreased among patients. After 3 months of enalapril treatment functional class improved significantly. The lactate dehydrogenase activity increased whereas the oxidative enzymes did not change significantly.
Introduction
In chronic heart failure, exercise capacity is limited by dyspnoea and fatigue. Haemodynamic variables, such as ejection fraction, pulmonary capillary wedge pressure, ventricular end-diastolic volume and cardiac index, measured at rest, correlate poorly with exercise capacity 1 " 41 . Other factors possibly limiting functional capacity, such as changes in the peripheral circulation and extracirculatory factors, have therefore been explored. Skeletal muscle blood flow is limited in patients with chronic heart failure 15 ' 61 , probably due to a combination of low cardiac output and increased peripheral resistance. Structural or metabolic changes in skeletal muscle could also be of importance. Investigations utilizing 3I P nuclear magnetic resonance spectroscopy have indicated an abnormal skeletal muscle metabolism' 7 ' l] . This finding is not influenced by altered blood flow 1 ' 21 . In the skeletal muscle of patients with chronic heart failure compared with normal subjects, there is also evidence of a reduced percentage of type I fibres with high oxidative enzyme content and an increased percentage of type II B fibres with high glycolytic capacity 113 " 151 . With regard to enzymatic changes, the results reported in the literature are not consistent. Some investigators have reported a reduction in oxidative enzyme activity 1 ' 4 
"
171 whereas others found no changes" 3 ' 181 .
Angiotensin converting enzyme inhibitors improve symptoms and prolong life in patients with chronic heart failure' 19 ' 201 . The present trial was conducted to elucidate if these beneficial effects are related to skeletal muscle factors. Skeletal muscle biopsies were analysed with respect to oxidative and glycolytic enzymes, glucose metabolism, muscle fibres and capillary density before and after 3 months treatment with the angiotensin converting enzyme inhibitor, enalapril. The hypothesis was that enalapril treatment would lead to improved symptomatology, increased physical activity and increased peripheral blood flow. It might also lead to increased activity of the oxidative enzymes, increased muscle fibre capillarization and increased size of individual muscle fibres. •Data are mean ± SD; NYHA, New York Heart Association.
Methods

Patient population
Twenty-six patients, 18 males and eight females, with chronic heart failure in New York Heart Association functional class II-IV and 20 age-matched normal individuals, 15 males and five females, were studied (Table 1) . All patients had a left ventricular ejection fraction of <; 40% range and a duration of heart failure of at least 2 months (range 2-204). Mean age was 68 years. The cause of heart failure was myocardial infarction in 15 patients, hypertension in two patients and idiopathic dilated cardiomyopathy in nine patients. All patients were on frusemide (range 20-200 mg) and 16 patients were receiving digitalis. None had previously been on angiotensin-converting enzyme inhibitors. Patients with diabetes mellitus, intermittent claudication, peripheral oedema, neuromuscular disorders, myocardial infarction within 2 months, obstructive valvular heart disease, angina pectoris limiting physical performance or significant pulmonary disease were excluded. The control subjects had no history of cardiovascular diseases, and had normal laboratory parameters, electrocardiogram, chest X-ray and physical examination. Percutaneous skeletal muscle biopsies were taken before and after 3 months treatment with enalapril. 
Skeletal muscle biopsy
Percutaneous biopsies were taken with a conchotome under local anaesthesia from the middle part of the lateral vastus muscle. In the patients who underwent exercise testing, the biopsy was made within 7 days of the exercise test. Two biopsy samples were immediately frozen in liquid nitrogen, stored at -70 °C and were used for analysis of metabolites and enzymes. A third sample was trimmed and mounted in embedding media, frozen in cooled isopentane and stored at -70 °C. This sample was used for histochemical analysis. 
Biochemical muscle analysis
Histochemical muscle analysis
The biopsy was cut with a cryotome, at -21 °C, in cross-sections (10 urn). The myofibrillar adenosinetriphosphate method was used for muscle fibre classification. The reactions were carried out at pH 9-4 following alkaline pre-incubation at pH 10-3'
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. Thereafter the fibres were classified into type I (slow twitch) and type II (fast twitch). The type II fibres were further classified into type II A, II B, and IIC after preincubations at pH 103, 4-6 and 4-4. Measurements of fibre areas were made with a semi-automated method (Comfas system, Bio-Rad Scan Beam A/S, Hadsund, Denmark). With amylase-PAS staining the capillaries were visualized and calculated according to Andersen and Henriksson' 271 .
Exercise testing
Ten patients and 10 control subjects underwent two consecutive exercise tests in an upright position on a bicycle ergometer. A ramp protocol with increases of 10W every minute until exhaustion was utilized. The first exercise test familiarized the subjects with the method. The second test was used as baseline. All patients and control subjects stopped exercise due to dyspnoea or fatigue, reaching level 17-19 on the Borg scale, where 20 is maximum
1281
. O 2 and CO 2 content in expired air was measured continuously breath by breath (Medical Graphics 2001 System minute ventilation, St Paul, Minnesota, U.S.A.). VO 2 max was defined as the VO 2 reached when VO 2 increased by < 1 ml. kg ~ ' . min ~ '. Where no plateau was found VO 2 max was defined as the average VO 2 during the last 30 s of exercise.
Haemodynamic measurements
Right-sided heart catheterization through the internal jugular vein was performed in eight patients within 1 week of muscle biopsy. Heart rate and rhythm were monitored continuously. Right atrial, pulmonary artery and pulmonary capillary wedge pressures were determined from the Swan-Ganz catheter. Cardiac output (where possible, a mean of three estimates) was measured using a thermodilution technique. The first registration was made in the supine position 15 min after insertion of the catheter. New measurements were made with the patient sitting on the bicycle, during exercise at anaerobic threshold and at maximal exercise.
Statistical analysis
Data are expressed as mean ± SD. An unpaired twosided Student's t-test was used to evaluate possible differences for between-group comparisons. Paired t-test was used to evaluate pre-and post-treatment differences. / > <005 was considered significant. When analysing changes in NYHA functional class, improvement was considered + 1, and deterioration -1. The patients who did not change in functional class were considered 0 and then excluded. McNemar's test was used and /><005 was considered significant.
Results
Three patients did not complete the study. One patient did not tolerate enalapril due to hypotension. Two patients were excluded, one because of the development of insulin-dependent diabetes during the study and the other due to a serious infection with worsened heart failure at the time of follow-up. One patient needed an increased dose of frusemide (from 120 to 160 mg) during the study. In another patient, diltiazem was changed to metoprolol and long-acting nitrates due to angina pectoris. In the remaining patients the medication was unchanged. The mean dosage of enalapril was 17-3 ± 109 mg (range 25-40 mg). In three patients the dosage was increased to 20 mg b.i.d. due to high blood pressure. Fourteen patients improved at least one NYHA class, nine patients did not change NYHA class and none deteriorated. The mean NYHA class changed from 2-8 ± 0-5 to 20 ± 0-6, F=00001.
Biochemical results
At baseline the citrate synthetase, 3-hydroxyacyl-CoA dehydrogenase and phosphorylase activities were significantly lower in the patients than in the control subjects, whereas lactate dehydrogenase activity did not differ between the groups (Table 2 ). After treatment with enalapril, lactate dehydrogenase activity increased (143 ±79 vs 170 ±81 umol.g"' ww.min" 1 , ,P=0-02, Fig. 1 ). Among the 14 patients who improved at least one NYHA class there was an even greater increase in lactate dehydrogenase (135 ± 48 vs 178 ± 78 umol . g~ ' ww.min"', P=0006). Muscle protein content was analysed in 22 of 23 patients. The results were not different if enzyme activity was expressed as umol . g~ ' ww.min"' or as nmol.g"' protein . min ~'. Therefore, all enzyme activities are expressed as umol. g ~ ' ww . min ~ '.
In the patient group adenosine triphosphate was lower compared with the control subjects (/ > =005, Table 2 ). Creatine phosphate, lactate, glucose-6-phosphate, glucose and glycogen did not differ significantly between the groups (Table 2) . 
Histochemical results
At baseline there was inadequate material in nine patients to make a histochemical analysis. At follow-up four biopsies were not adequate for analysis. In 10 control subjects histochemical analysis was not performed due to a freezer breakdown and in another two there was inadequate material. No difference in baseline characteristics was noticed between the control subjects where histochemical analysis was performed or not. The patients where histochemical analysis was performed had shorter duration of heart failure than the ones where no histochemical analysis was possible (15-6 ±18 vs 57-4 ± 66 months).
There was no significant difference in fibre type composition or fibre area between the groups (Table 3) . There were fewer capillaries/fibre in the patients than in the control subjects (/ > =0004, Table 3 ). The number of capillaries in contact with each fibre was significantly decreased in patients with chronic heart failure compared with controls in all fibre types (Table 3) . However, the capillary density did not differ between the groups (Table 3) .
After enalapril treatment the mean fibre area and the area of the type I, II and II A fibres increased significantly (Table 4 and Fig. 2 ). There was no change in relative fibre type distribution or relative fibre area at follow-up. No relationship between changes in fibre area and lactate dehydrogenase activity was noted. Capillary density, the number of capillaries in contact with each fibre and the fibre area in relation to the number of capillaries in contact with each fibre did not change significantly ( Table 4) .
Exercise testing
No difference in baseline characteristics was noted between the patients and control subjects who performed an exercise test and the ones who did not. At baseline, patients maximal workload was 687 ± 25-7 W with VO 2 max 11 -8 ± 2-7 ml. kg ~ ' . min " '. The normal subjects reached a significantly higher maximal workload and VO 2 (Table 1) . Six patients repeated the exercise test at the time of follow-up. Their exercise capacity increased from 76 W to 94 W (P=007). VO 2 max increased in five out of six patients but the average (13-6 ± 2-2 ml . kg" 1 . min" 1 ) was not significantly increased. 
Haemodynamic measurements
Heart rate at rest decreased significantly after enalapril treatment, 82 ± 16 beats. min Eur Heart J. Vol. 17. November 1996 vs 70 ± 13 beats . min ' (f > <0004) whereas blood pressure did not change (128 ± 22781 ± 12 mmHg vs 130 =f c 18/78 ± 11 mmHg). In eight patients, right-sided heart catheteration was done at baseline and in six the procedure was 
Discussion
This investigation was performed to evaluate if enalapril treatment influences skeletal muscle tissue in patients with chronic heart failure. Our results show that patients with chronic heart failure at baseline have decreased activity of citrate synthetase, 3-hydroxyacyl-CoA dehydrogenase and phosphorylase in skeletal muscle compared with normal subjects. No difference was found in lactate dehydrogenase activity in skeletal muscle between the patients and control subjects. There was a tendency towards a lower percentage of type I muscle fibres and a higher percentage of type II B muscle fibres in the patients compared with normal subjects. The patients had a decreased number of capillaries per fibre and fewer capillaries surrounding each fibre when compared with the control subjects. After enalapril treatment lactate dehydrogenase activity increased in skeletal muscle. The mean fibre area, the area of type I, II and II A fibres increased also after enalapril treatment.
Muscle fibre changes
In normal subjects there is a difference in muscle fibre area between men and women 1291 . In our material there is no significant difference in the proportion of men and women in the chronic heart failure group compared with the control group. Data are therefore not presented separately for men and women. Others have reported a lower percentage of type I fibres and a higher percentage of type II B fibres in patients with chronic heart failure compared with normal subjects' 13 "
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. We found a trend towards such a change in fibre type composition but it did not reach statistical significance. This might be due to the limited number of control subjects in our material. When comparing our patients with another control group from the same laboratory containing 53 control subjects' 291 , the patients had a lower percentage of type I fibres and higher percentage of type II B fibres than the controls. A decreased type II fibre area have been reported by some investigators' 14 " 151 , whereas others have not found such a change 1131 . In our material there was a trend towards smaller muscle fibres in the patients but it did not reach statistical significance. After enalapril treatment our patients improved in functional class. The fibre area of the type 1 and type II fibres increased significantly after enalapril in our patients which might be due to an effect of increased physical activity or increased skeletal muscle blood flow. A similar increase in muscle fibre area is seen in normal subjects after physical training 
Capillarization
The number of capillaries/fibre and number of capillaries in contact with each fibre were decreased in our patients at baseline compared with the normal subjects. This is in accordance with the results of 311 in normal subjects. The decreased capillarization in patients with chronic heart failure could be due to inactivity or reduced skeletal muscle blood flow. Disturbed capillary distribution might contribute to the decreased exercise capacity and earlier onset of lactate accumulation seen in patients with chronic heart failure. Enalapril could not influence the capillarization of the lateral vastus muscle. It is possible, however, that a 3 months treatment period is too short to detect such changes.
Enzymatic changes
Citrate synthetase, an enzyme representing the citric acid cycle, and 3-hydroxyacyl-CoA dehydrogenase, an important enzyme in the oxidation of fatty acids, were significantly decreased in the patients at baseline compared with controls. These results are in accordance with others' 14 " 171 . In other reports, however, there were no changes in oxidative enzymes possibly due to smaller material' 13 ' 181 . Reduction in training is associated with a decline in activity of oxidative enzymes in normal subjects' 32 '. There are data suggesting that training can influence oxidative enzymes in patients with chronic heart failure 133 ' 341 . The decreased physical activity in patients with chronic heart failure most probably partly explains the enzymatic changes found in this patient group.
The enzyme phosphorylase, involved in glycogenolysis, was also significantly decreased at baseline in the patients compared with normal subjects. Lactate dehydrogenase, which here represents glycolysis, did not differ significantly between the patients and the control subjects at baseline. Sullivan et al. found no difference in phosphorylase or lactate dehydrogenase activity in patients with chronic heart failure compared with controls'
151 . The different results might be explained by differences in patient selection. The decreased phosphorylase activity in our patients might be due to immobilization. However, this is unlikely because most of our patients were in NYHA class II and III and decreased phosphorylase activity has only been seen after complete immobilization' 351 . A defect in enzyme synthesis might explain the decreased enzyme activities found in our material. If this is the case, it cannot be concluded from this investigation. In a recently published investigation Stratton et al. found that increased phosphocreatine depletion seen in skeletal muscle in patients with chronic heart failure is not totally reversible after cardiac transplantation' 36 '. This may support the theory of an intrinsic defect in skeletal muscle in chronic heart failure.
Interestingly, lactate dehydrogenase was the only enzyme which increased in activity after 3 months enalapril treatment. The increase was most marked among patients who improved in NYHA class. One possible explanation might be that patients increased their physical activity while the blood and oxygen supply to working muscles did not increase correspondingly. Anaerobic metabolism would then be more utilized. The decreased muscle mass found in patients with chronic heart failure* 37 ' 381 might increase the demand on each muscle fibre leading to increased anaerobic metabolism. Increased activity of glycolytic enzymes has been seen after high intensity training 139401 . It is possible that the increased physical activity in our patients, as reflected in the change in NYHA class, gives training effects of a similar kind. Sylven et al. found an increase in phosphofructokinase, a rate limiting enzyme in the glycolytic pathway, after treatment of patients with chronic heart failure with captopril'
181 . This may support our results. Furthermore, patients with peripheral arterial insufficiency, a state of underperfused skeletal muscle, have increased levels of lactate dehydrogenase* 41 '. Another possible explanation would be an intrinsic defect in the oxidative pathway not detectable when measuring the enzymatic activity in vitro. A specific enalapril effect on skeletal muscle, increasing lactate dehydrogenase, cannot be excluded.
Metabolic changes
When investigated with 3I P nuclear magnetic resonance spectroscopy, patients with chronic heart failure have no changes at rest, but do experience impaired skeletal muscle metabolism during exercise with a faster decrease in pH and greater phosphocreatine depletion' 7 ' 8 '°"' 421 . Adenosine triphosphate was decreased in our patients and a decreased glycogen level has been reported from others' 4344 '. Broqvist et a/.' 431 further noticed decreased adenosine triphosphate and phosphocreatine levels. These findings in patients with chronic heart failure may be explained by increased glycolytic metabolism during daily activities or by malnutrition, which has been reported in patients with chronic heart failure 1361 . Longterm treatment with enalapril among our patients did not influence the glucose metabolism in skeletal muscle at rest. Similar findings were made by Broqvist et a/.' 431 .
Limitations of the study
Not all patients and control subjects were investigated histochemically. The number of patients investigated, however, was enough to show changes in fibre area after 3 months treatment with enalapril. There was also a trend towards an increase in capillarization after treatment. The limited number of control subjects investigated histochemically makes the comparison between patients at baseline and controls precarious. Accordingly, other control material has also been utilized as mentioned above. Another objection may be that the metabolic results are expressed in mmol. kg~' ww. Broqvist et al. found increased water content in skeletal muscle in 22 patients with oedema'
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. On the other hand Dyckner et al. did not see any significant change of skeletal muscle water content in 297 patients with heart failure'
461
. Our patients were all without oedema which makes it reasonable to believe that the metabolic results were not influenced by increased skeletal muscle water content.
Summary
Our results show that patients with congestive heart failure have reduced activity of oxidative enzymes as well as the glycogenolytic enzyme phosphorylase in skeletal muscle and decreased muscle capillarization. After enalapril treatment patients with chronic heart failure improved in functional class, increased lactate dehydrogenase activity and the fibre area in skeletal muscle.
